Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,868 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DGKA Mediates Resistance to PD-1 Blockade.
Fu L, Li S, Xiao W, Yu K, Li S, Yuan S, Shen J, Dong X, Fang Z, Zhang J, Chen S, Li W, You H, Xia X, Kang T, Tan J, Chen G, Yang AK, Gao Y, Zhou P. Fu L, et al. Among authors: you h. Cancer Immunol Res. 2021 Apr;9(4):371-385. doi: 10.1158/2326-6066.CIR-20-0216. Epub 2021 Feb 19. Cancer Immunol Res. 2021. PMID: 33608256
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH. Xu-Monette ZY, et al. Among authors: you h. Cancer Immunol Res. 2019 Apr;7(4):644-657. doi: 10.1158/2326-6066.CIR-18-0439. Epub 2019 Feb 11. Cancer Immunol Res. 2019. PMID: 30745366
PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH. Li L, et al. Among authors: you h. Mod Pathol. 2019 Jun;32(6):741-754. doi: 10.1038/s41379-018-0193-5. Epub 2019 Jan 21. Mod Pathol. 2019. PMID: 30666052 Free article.
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY, Li J, Xia Y, Crossley B, Bremel RD, Miao Y, Xiao M, Snyder T, Manyam GC, Tan X, Zhang H, Visco C, Tzankov A, Dybkaer K, Bhagat G, Tam W, You H, Hsi ED, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Winter JN, Medeiros JT, Xu B, Li Y, Kirsch I, Young KH. Xu-Monette ZY, et al. Among authors: you h. J Immunother Cancer. 2019 Oct 22;7(1):272. doi: 10.1186/s40425-019-0730-x. J Immunother Cancer. 2019. PMID: 31640780 Free PMC article.
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Hagemeister F, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Liu P, Young KH. Deng M, et al. Among authors: you h. Mol Cancer Res. 2021 Feb;19(2):249-260. doi: 10.1158/1541-7786.MCR-20-0466. Epub 2020 Nov 5. Mol Cancer Res. 2021. PMID: 33154093 Free PMC article.
2,868 results